Austar Lifesciences (HKG:6118) expects to record an attributable profit of not less than 30 million yuan for 2025, up from about 16 million yuan a year earlier, according to a Friday Hong Kong bourse filing.

The company attributed the increase mainly to lower operating expenses, including reduced administrative and research and development costs, as well as higher other gains, driven largely by exchange gains, and lower finance costs.